Two Roads Diverge For Mylan: Teva Or Perrigo
This article was originally published in The Pink Sheet Daily
Teva announced a proposal to acquire Mylan for $82 per share, or roughly $40 billion, putting Mylan’s independence and a proposal to acquire OTC drug specialist Perrigo in question. Adding to the uncertainty, Perrigo rejected Mylan’s offer after market close.
You may also be interested in...
Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.
The situation is still fluid on a possible merger between Teva and Mylan and will likely see a few quick and dramatic turns over the next few weeks. In the event a deal does click, it would have a significant impact on the two firms’ Indian businesses and also Indian generic manufacturers more generally.
Teva is aggressively developing a fully substitutable generic version of Advair and other AB-rated respiratory products now that FDA has released draft guidance on bioequivalence requirements for the inhaled respiratory drug.